On November 28, 2024, Eisai Co., Ltd. and Biogen Inc. announced the launch of their humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, LEQEMBI® (lecanemab), in South Korea. This launch follows the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for the treatment of adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, collectively referred to as early AD.
LEQEMBI is the first approved treatment demonstrated to reduce the rate of disease progression and slow cognitive and functional decline by selectively binding to soluble Aβ aggregates (protofibrils) and insoluble Aβ aggregates (fibrils). These protofibrils are considered highly toxic and play a primary role in the cognitive decline associated with AD.
Eisai Korea Inc. will be responsible for distributing the product and conducting information provision activities in South Korea. The company plans to initially launch LEQEMBI in the private market, including the establishment of a Patient Assistance Program, to ensure access for patients awaiting treatment. This expansion into South Korea, where approximately 900,000 people were estimated to have dementia in 2021, represents a significant step in making this disease-modifying therapy available globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.